Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
What about if you use this in adjuvants?
Could you, I mean, I know I'm pushing my luck here or at least pushing the luck of biology here.
Could it be possible they can prevent it?
And why is it important for patients not to get ESR1 mutations?
Okay, I think I'll move on to, there's a risk that this ends up being entirely about breast cancer, but there were the two big things, but I really want to cover some bladder before we move on, before we end.
But let's just talk about tropion breast O2 trial.
This is Datraway, TROP2 ADC.
The data, and I'm sure you'll, again, go through the detail a little bit more here,
They just seem better on a response rate basis.
And, you know, this is what we do all our lives, comparing trials, which shouldn't be compared, but there's nothing else we can do.
Otherwise, we wouldn't have a job.
Versus trotelvi in PD-L1 negative, triple negative breast cancer patients.
The OS, on the other hand, is complicated by the different post-progression treatments, for instance, in TBO2 versus Acendo3, which was the Gilead-Tridelby trial.
Given all this, how important do you think OS is in the trial, which may have been driven by post-progression issues, etc.
?
Yeah, agreed.
The one thing I do hear from physicians, though, is the stomatitis issue, which even though, okay, 57% in the, if I'm not wrong, in the TBO2 trial, but majority were low grade.
Even the low grade seems to bother people a little bit, I
Do you think this is something about learning to manage it as we go forward?
Because physicians seem to be always good at dealing with the side effects of cancer drugs to the point that they can.
Showing 801–820 of 906 · page 41 of 46
← Previous
Next →